Teva gains leverage in pursuit of Mylan | Pittsburgh Post-Gazette
Drugmaker Teva makes $40B bid for rival Mylan
Teva Pharmaceutical Industries Ltd. ends its hostile bid for Mylan NV - Pittsburgh Business Times
Teva Issues New Letter to Mylan NV Confirming Seriousness Of Offer To Acquire Mylan - Jewish Business News
Teva wins FDA nod for its generic of Mylan's EpiPen after 2-year delay | Fierce Pharma
The Teva-Allergan deal shows why pharma mergers are booming | Fortune
Teva responds to Mylan backlash with planned launch of generic EpiPen | Healthcare IT News
Teva Makes Hostile Bid To Acquire Mylan
Generic EpiPen Cleared By FDA As Teva Challenges Mylan
Teva's Copaxone holds its own in wake of Mylan's generic price cut | Fierce Pharma
Mylan Rejects Teva Takeover Bid As Too Low | Mint
Teva's Generic EpiPen Will Cost As Much As Mylan's Generic | Time
Teva offers to buy Mylan in $40 billion deal | The Times of Israel
$40B deal: Teva offers to buy Mylan
FDA swats down Teva's EpiPen copy, putting Mylan in cruise control | Fierce Pharma
Teva drops bid for Mylan, buys Allergan's generics unit | Pittsburgh Post-Gazette
Mylan board rejects Teva takeover bid
Mylan Raises Offer for Perrigo Again and Is Rejected Again - The New York Times
Teva Pharmaceutical Industries' quest to acquire Mylan NV could wind up in a Dutch court - Pittsburgh Business Times
Mylan NDEA contamination prompts Teva recall in US
Mylan surprises analysts, Teva with long-delayed Copaxone approvals | Fierce Pharma
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Teva makes $40 billion offer for Mylan
